

# Ben Browning Portfolio



Access Infinity  
2020 – Present

Lead Designer

Nuro is a data platform designed to research drugs approved for use since 1995.

Pharmaceutical companies use this tool to research:

- Regulatory Information
- Price Changes
- HTA Data
- Clinical Trial Data
- ...more

I joined the company just as we were about to initiate a re-design of the legacy platform which only had a single customer.

Since my re-design of the platform we have onboarded 80% of top pharmaceutical companies as users

This product has achieved an ARR of ~\$3MM since the re-design  
A growth of ~4,900%



## Non-small cell lung carcinoma

Oncology


Overview Build a Chart Competitor Landscape Price Evolution Pipeline Competitor Activity HTA Tracker Payer Panel AI

All Brands ▾ All Countries ▾ All Manufacturers ▾ All Time ▾ All HTA Publications ▾

Timeline View

Total Number of HTA Publications **108** +2 this month

ICER	United States	19 Publications
HAS	France	24 Publications
G-BA	Germany	20 Publications
AIFA	Italy	3 Publications
AEMPS	Spain	8 Publications
NICE	England	2 Publications
SMC	Scotland	1 Publications
TLV	Sweden	6 Publications
CHUIKYO	Japan	5 Publications
CADTH/pCODR	Canada	3 Publications
PBAC	Australia	1 Publications
Ministry of Health	China	2 Publications
CONITEC	Brazil	4 Publications
HIRA	South Korea	10 Publications



Search

Show: LATEST HTA PUBLICATIONS

ANTICIPATED FUTURE PUBLICATIONS

Download

Region	Brand Name	Date	Outcome	Initial / Reassessment	Reimbursed
Italy	Lumrakas NSCLC (met, KRAS G12C+, systemic therapy IR, in adults)	17 Dec 2024	<span>Class H</span>	Initial Assessment	Yes
Germany	Enhertu NSCLC (met, HER2, ERBB2 mutations, 1L)	16 Dec 2024	<span>No Additional Benefit</span> +1 Other Outcome	Initial Assessment	Yes
Sweden	Lumrakas NSCLC (met, KRAS G12C+, systemic therapy IR, in adults)	16 Dec 2024	<span>Recommended with Restrictions</span>	Reassessment	Yes
Brazil	Imiude	16 Dec 2024	<span>Other Outcome</span>	Initial Assessment	Yes

## Filters Applied 6

Regulatory Agency is "FDA", "EMA",

Therapy Area is "Non-small cell lung

HTA Publication date between "1 Jan

HAS Publication (France) includes "A

Branded / Biosimilar / Generic is "Br

Route of Administration is "Intraver

Results

216 /7,853

INNs

158 /1,815

Results Table

Price Insights

Search results

 Brand Name Expand all Abecma  
Multiple myeloma (relapsed or re... Abilify Maintena  
Schizophrenia (in adults) Abraxane  
mBC (CT IT) Abraxane  
Pancreatic cancer (met naïve)

Search for a filter

Fixed Dose Combination

Evidence

Pivotal Studies

Cost Effectiveness Metrics

Regulatory Status

Regulatory Agency

Approval Date

Time to Event

Conditional Approval

Orphan Status

Product Positioning

Order of Entry

Line of Treatment

Target Population Size

Adjunct / Combination Use

Biomarker Use

HTA Assessment

HTA Agency

Price

Price (Cost of Treatment)

Price Differential

Flat/Linear Pricing

## HTA Agency

CLEAR

Explore HTA Publications across key global markets

## Date Range

Start Date

14 Feb 1996

End Date

Today



ICER United States

HAS France

G-BA Germany

AIFA Italy

AEMPS Spain

NICE England

SMC Scotland

TLV Sweden

CHUIKYO Japan

CADTH /pCODR Canada

PBAC Australia

Ministry of Health China

CONITEC Brazil

HIRA South Korea

CLEAR ALL

CANCEL

Apply

Remove All

Remove



## Non-small cell lung carcinoma

Oncology

Overview

Build a Chart

Competitor Landscape

Price Evolution

Pipeline

Competitor Activity

HTA Tracker

Payer Panel

AI

Select Products

Chart Settings

Apply Changes

Chart Type

Scatter Chart

Select Country

France

X-Axis

Regulatory Approval (EMA)

Y-Axis

Annual Cost of Treatment at Launch (EUR)


Bubble Colour [Legend]

Study Type

Bubble Size

## France – CoT and Relative Improvement (%) by Study Type

Download



Search results

Edit Columns

View Selection

Default ▾

Download

<input type="checkbox"/> Brand Name <span>Expand all</span>	INN	Indication	Branded / Biosimilar / Generic	United States C.O.T <span>i</span>	EU4+UK Avg. C.O.T <span>i</span>	HAS Publication	G-BA
<input type="checkbox"/> <a href="#">Abevmy</a> NSCLC (non-squamous, met, in co...)	bevacizumab	Non-small cell lung carcinoma	Biosimilar	Not FDA Approved	€ 46,156.45	ASMR V	N
<input type="checkbox"/> <a href="#">Abraxane</a> NSCLC (naïve, surgery or RT IT)	paclitaxel	Schizophrenia	Branded	\$ 164,890.55	€ 30,519.18	ASMR V	Not As
<input type="checkbox"/> <a href="#">Alecensa</a> Breast cancer	alectinib	Breast cancer	Branded	\$ 236,996.50	€ 71,501.60	ASMR IV	Not As



## Price Explorer

11 Products Selected

Exchange Rates

Edit Assumptions

## United States

Avg. body weight for adults

75 kg

Avg. body surface area for adults

1.79 m<sup>2</sup>

## GENERAL ASSUMPTIONS

Applicable to all countries

Months in a year

12

Days in a year

365.25

No. of days in a month

30.437

Price per year

Manufacturer Price

Key Markets

Default Pack

Default

Download


Brand Name	KEY MARKETS														EMA			
	US	JP	DE	FR	BR	BE	HR	CZ	DK	ENG	EE	FI	GR	IT	NO			
Cibinquo Atopic dermatitis (moderate to severe, systemic therapy IR)	✓ \$32.7K	✓ ¥595.7K	✓ €6.1K	✓ €6.5K	✓ R\$26.8K	✓ €8.0K	✓ €6.5K	Kč151.8K	kr36.6K	£4.7K	X	✓ €5.1K	✓ €5.4K	✓ €8.4K	✓ kr60.0K			
Dupixent Atopic dermatitis (moderate to severe, systemic therapy IR)	✓ \$55.9K	✓ ¥1.5M	✓ €14.7K	✓ €15.9K	✓ R\$110K	✓ €14.9K	✓ €16.4K	Kč410.6K	kr108.4K	£15.5K	X	✓ €14.4K	✓ €14.8K	X	✓ kr162.2K			
Ebglyss Atopic dermatitis (moderate to severe, systemic therapy IR)	X	X	✓ €17.5K	X	✓ R\$121K	✓ €18.1K	✓ €24.1K	X	X	X	✓ €21.2K	✓ €3.2K	X	X	X			
Protopic Atopic dermatitis (moderate to severe, systemic therapy IR)	✓ \$1.5K	✓ ¥9.6K	✓ €203	✓ €100	✓ R\$727	✓ €67	✓ €120	Kč3.1k	kr1.6K	£133	X	✓ €166	✓ €94	✓ €148	✓ kr1.1K			
Rinvoq Atopic dermatitis (moderate to severe, systemic therapy IR)	✓ \$82.2K	✓ ¥1.3M	✓ €11.4K	✓ €7.2K	✓ R\$25.2K	✓ €9.7K	✓ €8.5K	Kč175k	kr73.4K	£10.5K	X	✓ €8.8K	✓ €8.2K	X	✓ kr92.1K			

Germany ▾ List Price per year ▾

Default Pack

USD

Download



- Cibinquo**  
Atopic dermatitis (moderate to severe, systemic therapy IR)  
\$2,448.70
- Dupixent**  
Atopic dermatitis (moderate to severe, systemic therapy IR)  
\$2,448.70
- Olumiant**  
Atopic dermatitis (moderate to severe, systemic therapy IR)  
\$2,448.70
- Rinvoq**  
Atopic dermatitis (moderate to severe, systemic therapy IR)



Access Infinity  
2020 – Present

Lead Designer

Access Hub is a platform designed for pharmaceutical companies to track the launch of their drugs globally.

The platform is highly customisable for each customer, and is commonly used to track:

- Regulatory Approvals
- Reimbursement Decisions
- Regional Contracts & Agreements
- Key Milestones & Launch Tracking
- Brand Specific KPIs & Portfolio Tracking

I lead the process of re-designing the legacy instances of the platform, and converting the tool in to a true SaaS application.

Between May 2024 → Jan 2025 I was interim product manager for the tool

In December 2024 I traveled to New York to meet with the Global Directors for Oncology at Pfizer and secured our first ever enterprise-level deal worth ~\$3.2MM



## Welcome back to Access Hub

Please enter your email and password to continue.

Email

Password

Log In

[Forgot Password?](#)

ZB Zorvinextra Balurema ▾

Search anything... 38K

## ACCESS DASHBOARD

[Dashboard Summary](#)[Reimbursement Overview](#)[Map View](#)[Reimbursement Timeline](#)[Launch Sequence](#)[Access Criteria](#)[Sub-National Access](#)[Contracts Overview](#)

## KPI TRACKER

[COMPETITOR INSIGHTS](#)[SPREADSHEET VIEW](#)

## FAVOURITES


[Spain](#)[France](#)

⚠ Filters applied to markets. Charts will only display the data of your chosen filters.

## Public National Reimbursement – Melanoma

Advanced Settings ▾

Download

● Full Reimbursement ● Restricted Reimbursement ● Reimbursement Rejected ● Dossier Submitted ● Outside Commercial Scope ● OOP Launch
[View Multi Access Channels](#) →[View Sub-National Access](#) →[Public National Reimbursement](#) →

Europe 27

APAC 19

North America 3

LATAM 8

[Private Insurance/HMO](#) →

Europe 27

APAC 19

North America 3

LATAM 8

[Hospital Access](#) →

COUNTRY	ACHIEVED ACCESS	REIMBURSEMENT STATUS	ACCESS DATE	ACCESS CRITERIA
France	BMI < 35 + ORCS	● Restricted Reimb. – Payer Imposed	May 8, 2024	BMI < 35 + ORCS +2
Germany	✓	● Reimbursed Per Label	May 8, 2024	BMI < 45 + 2 ORCS +1
Spain	SEEKING ACCESS	● Dossier Submitted		
Italy	✓	● Reimbursed Per Label	May 8, 2024	BMI < 35 + ORCS



ZB Zorvinextra Balurema ▾

Search anything... 38K

## ACCESS DASHBOARD

[Dashboard Summary](#)[Reimbursement Overview](#)[Map View](#)

## Reimbursement Timeline

[Launch Sequence](#)[Access Criteria](#)[Sub-National Access](#)[Contracts Overview](#)

## KPI TRACKER

## COMPETITOR INSIGHTS

## SPREADSHEET VIEW

## FAVOURITES

[Spain](#)[France](#)

⚠ Filters applied to markets. Charts will only display the data of your chosen filters.

## Reimbursement Tracking Timeline

Download

Hodgkin Lymphoma

Melanoma

Breast Cancer

REIMBURSED

REIMBURSED

REIMBURSED

31 /65 markets

41 /65 markets

60 /65 markets

◆ Full Reimbursement ◆ Restricted Reimbursement ◆ Reimbursement Rejected ◆ Reimbursed Early ◆ Custom Achievement


ZB Zorvinextra Balurema ▾

Search anything... 38K

## ACCESS DASHBOARD

[Dashboard Summary](#)[Reimbursement Overview](#)[Map View](#)[Reimbursement Timeline](#)[Launch Sequence](#)[Access Criteria](#)[Sub-National Access](#)[Contracts Overview](#)

## KPI TRACKER

## COMPETITOR INSIGHTS

## SPREADSHEET VIEW

## FAVOURITES

[Spain](#)[France](#)

## Launch Sequence – Merkel Cell Carcinoma

Overlay: Reimb. Status ▾

Merkel Cell Carcinoma ▾

Download





**Bank of England**


**Bank of England  
2019–2020**

**Product Designer**

In my previous role with a company called ‘ClearPeople’ – we enhanced, and maintained the website for the Bank of England.

I ran workshops with the BoE team to enhance their website’s navigation, landing page, and news results page.

The core structure of these pages remained largely unchanged with the focus being on improving the visual hierarchy, readability, and filtering of content.



# The Bank of England

Promoting the good of the people of the United Kingdom by maintaining monetary and financial stability.

Search the Bank of England



**£10bn**

Corporate Bond Purchase Scheme

**1.8%**

Current inflation rate  
Target 2.0%

Bank Rate maintained at 0.75% - January 2020

Our Monetary Policy Committee has voted by a majority of 7-2 to maintain Bank Rate at 0.75%. The committee also voted unanimously to maintain the stock of corporate bond purchases and UK government bond purchases. [Read more](#)

The new 20 note

## Banknotes

- [Current banknotes](#)
- [Upcoming banknotes](#)
- [Withdrawn banknotes](#)
- [Counterfeit banknotes](#)

[See more](#)

## Financial stability

- [Stress testing Resolution](#)
- [The Financial Policy Committee \(FPC\)](#)
- [Financial market infrastructure supervision](#)
- [Financial sector continuity](#)

[See more](#)

## Gold

Find out about gold at the Bank of England and [see our current gold holdings](#).

## Markets

- [The Sterling Monetary Framework](#)
- [The Asset Purchase Facility](#)
- [Other market operations](#)
- [Foreign currency reserves](#)

[See more](#)

## Monetary policy

- [Quantitative easing](#)
- [Inflation](#)
- [The Monetary Policy Committee \(MPC\)](#)
- [Interest rates](#)

## Prudential regulation

- [What does the PRA do?](#)
- [Policy](#)
- [Authorisations](#)
- [Supervision](#)

[See more](#)

## Research

- [Our researchers](#)
- [Research events](#)
- [Research themes and topics](#)
- [Funding and fellowships](#)

[See more](#)

## Payment and settlement

- [RTGS Renewal Programme](#)
- [Inflation](#)
- [CHAPS](#)
- [Banking services](#)



Inflation calculator



Get involved



How to exchange old Bank of England banknotes

## News & Events

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

6 April 2020

This is a single line

6 April 2020

The length of this title will wrap up to three lines before collapsing in to an ellipsis here...

6 April 2020

This title only wraps across two lines before collapsing in to an ellipsis here...

Home / News and publications

# News, publications and events

Latest and upcoming releases from the Bank of England

Filter

All filters

## Related links

- [RSS feeds](#)
- [Subscribe to emails](#)



[Clear All](#) | [Close Filter](#)

[Latest](#) | [Upcoming](#)

## Filter by type

- Bank Overground
- Event
- Knowledge Bank
- News
- Prudential Regulation
- Publication
- Speech
- Statistics

[Clear](#)

## Filter by topic

- Quarterly Bulletin
- News Release
- Monetary Policy Committee (MPC)
- Research
- Working Paper
- Monetary Policy
- Financial Policy Committee (FPC)
- Weekly Report

[Clear](#)

## Date

From:

To:

[Clear](#)

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line

6 April 2020

The maximum length title will wrap across 3 lines before collapsing in to an ellipsis here...

Publication // Weekly Report // Wrap to second line



Korn Ferry  
2019–2020

Product Designer

In my previous role with a company called ‘ClearPeople’ – we designed a SaaS tool named ‘Atlas’.

Atlas is an intranet system built on top of the legacy version of Microsoft Sharepoint. The following shows one of our client’s instances which won NN/g ‘Intranet of the Year’ UX award in 2020.



**KORN FERRY |**

# fuse

Search | Fuse |

News and events | What we do | Working with clients | Working at Korn Ferry | People and offices | Explore

People and Offices > Our Offices > Zurich

**Zurich**

**ON THIS PAGE**

**OFFICES**

- APAC
- EMEA
- NA
- LA

**ADMIN LINKS**

- News
- Events
- Office Closures
- Office Contacts
- Documents
- Quick Links
- Spotlights

**ZURICH**

**CONTACT INFORMATION**

Prime Tower  
Hardstrasse 201  
8005 Zürich  
Switzerland  
+41 43 366 77 88  
reception\_zurich@kornferry.com

**KEY CONTACTS**

- Stefan Steger | Senior Client Partner, Country Chairman
- Sandra Meier | Administrative Office Manager
- Isabelle-Anne Waber | Receptionist

**MORE** **VIEW CONTACTS**

**IN FOCUS**

EMEA Travel page

Zurich office directions

Switzerland phone list

Prime Tower Emergency Plan

**OFFICE** **COUNTRY** **REGION**

Welcome Annika Reinhart

25 Feb 2019

KORN FERRY HIS WEEK IN LEADERSHIP

17 Jan 2019

January 17, 2019

Lessons in leadership from this week's news, as reported by our team.

01 02 03 **ALL NEWS**

**RECENT DOCUMENTS**

**THE OFFICE** **POLICIES & PROCEDURES**

- Switzerland Phone List Internal
- Zurich office absence form | Template | Jan 2019
- KF Switzerland | Organisation chart | Oct 2018
- Zurich | PrimeTower directions | Map | Oct 2018

**OFFICE STATUS**

**OFFICE CLOSED**  
REASON FOR CLOSURE HERE...

**CLOSURE DATE** 26FEB **EXPECTED OPEN** 11MAR

**VIEW ALL**

**UPCOMING OFFICE CLOSURES**

8APR 19APR - 22APR 1MAY

**ALL CLOSURES**

**EVENTS**

25MAR Zurich Office Meeting

01 02 **ALL EVENTS**

**OUR COMMUNITIES**

FEATURED KF Switzerland

**GROUP EXPLORER**

**QUICK LINKS**

- ZVV timetable - Zurich's Buses, Trams, Trains
- Swiss and Zurich Public Holidays
- Zurich Tourism
- Zurich City time-lapse video

**SHARE**

**KORN FERRY |**

# fuse

Search | Fuse |

News and events | What we do | Working with clients | Working at Korn Ferry | People and offices | Explore

People and Offices > People directory

**Search** | **People** |

Some here is some text and we can bold this and have a link to stuff

**FILTERS**

- Geography
- Solution Area
- COE
- Market
- Line of Business
- Function

**Clear All**

About 10,705 results

	A.J. D'Antonio Managing Consultant		AJ Stewart Senior Recruiter		Aadesh Sthapit ITG - Service Desk Engineer (Contractor)		Aakaash Jain Research Associate
	Aakanksha Bhatt Managing Consultant		Aakansha Pandey Talent Acquisition Consultant		Aaron Aw CD/Associate Consultant		Aaron Jones ITG Agency - Service Desk Engineer x30 (Contractor)
	Aaron Judd ITG - Service Desk Engineer (Contractor)		Aaron Reinhart Senior Recruiter		Aaron Cikaya Recruitment Coordinator		Aarti Barai Recruitment Consultant
	Aarti Patel Recruitment Coordinator		Aaryn Wilkinson Sr. Project Coordinator		Aasif Qureshi Comm:Client Relationship Manager		Abbe Ulrich Senior Client Partner
	Abby Brewer Recruiting Coordinator		Abby Kingsley Senior Project Coordinator		Abby Walker CD:Client Service Associate		Abby Peng Recruitment Consultant
	Abby Dayao Senior Sourcing Consultant		Abby Qi Senior Recruitment Consultant		Abby White Associate Principal		Abby Zhang Senior Recruitment Consultant

**DOWNLOAD A BIO**

- BIO\_Apr\_2019
- BIO\_A&S\_FS\_Apr\_2019
- BIO\_A&S\_FS\_Jul\_2019



Graphic Design Work  
2015–Present

Misc. Print & Digital Design

My degree from the University of the Arts London was in Graphic Design.

I was specifically interested in grid systems, typography, archival design, and branding.

I began with the Adobe Suite in 2009 which lead to my interest in graphic design — prior to my studies I learnt the basics of front-end coding. The mix of these two fields, and my love for technology is what has ultimately lead to my career in Product Design.

The following are some quick examples of work produced before 2018.

My dissertation was titled ‘On the use of technology within sports and games as a means of enhancing human performance’

Four bright lights in diamond formation were sighted at 1745 by a captain and a lieutenant flying in aircraft south of Wisconsin. The pilots followed them until they overtook the objects and continued following them low on fuel at which point they returned to their base. AT no time was a silhouette visible, even against the lights of Milwaukee. Visibility was almost unlimited with a broken cloud deck at 25,000 feet. The observing aircraft was at an altitude of 8,000 feet.



→ Wisconsin, USA  
9 December, 1952

[04] Four bright lights in diamond formation were sighted at 1745 by a captain and a lieutenant flying in a T-33 aircraft south of Madison, Wisconsin. The pilots followed until they overtook the objects and continued following them low on fuel at which point they returned to their base. AT no time was a silhouette visible, even against the lights of Milwaukee. Visibility was almost unlimited with a broken cloud deck at 25,000 feet. The observing aircraft was at an altitude of 8,000 feet.

Conclusion:  
Unknown


04 Maxwell Project Blue Book #1  
<http://www.bluebookarchive.org/>  
PID — MAXW-PBB1-753

**F**our bright lights in diamond formation were sighted at 1745 by a captain and a lieutenant flying in a T-33 aircraft located south of Madison, Wisconsin. The pilots followed until they overtook the objects and continued following them until low on fuel at which point they returned to their base. AT no time was a silhouette visible, even against the lights of Milwaukee. Visibility was almost unlimited with a broken cloud deck at 25,000 feet. The observing aircraft was at an altitude of 8,000 feet.

04 Maxwell Project Blue Book #1  
<http://www.bluebookarchive.org/>  
PID — MAXW-PBB1-753



MOD Sighting Reports: 2002



Ei  
jo  
th  
M  
in  
th  
together again in  
a circle.

In 776 the Saxons rebelled against Charlemagne and attacked the castle of Syburg with continued lack of success, finally deciding to storm the castle. They "saw the likeness of two shields red with flame wheeling over the church. When the heathens outside saw this miracle, they were at once thrown into confusion and started fleeing to their camp in terror. Since all of them were panic-stricken, one man stampeded the next and was killed in return, because those who looked back out of fear impaled themselves on the lances carried on the shoulders of those who fled before them. Some dealt each other aimless blows and thus suffered divine retribution"

→ Syburg Castle, Germany  
776

MOD Sighting Reports: 2002

Object looked like an upturned saucer with a dome had had had top. hov



